Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: A uniocular switch study

Journal of Glaucoma

Volumn 18, Issue 8, 2009, Pages 582-588

  Casson, Robert J ^a   Liu, Lance ^b   Graham, Stuart L ^c,d,e   Morgan, William H ^f   Grigg, John R ^e   Galanopoulos, Anna ^b   Crawford, Andrew ^g   House, Philip H ^h  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^c Eye Associates

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f MACQUARIE UNIVERSITY   (Australia)

^g NORTHERN HOSPITAL   (Australia)

^h Applecross Eye Care   (Australia)

Author keywords

Bimatoprost; Latanoprost; Ocular hypertension; Open angle glaucoma; Prostaglandin analogs

Indexed keywords

BIMATOPROST; LATANOPROST; AMIDE; CLOPROSTENOL; DRUG DERIVATIVE; PROSTAGLANDIN F;

AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROMA; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LID HYPEREMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; ADULT; CHEMICALLY INDUCED DISORDER; CONJUNCTIVA DISEASE; CROSSOVER PROCEDURE; DRUG EFFECT; HEADACHE; HYPEREMIA; MIDDLE AGED; PATHOPHYSIOLOGY; RETREATMENT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMIDES; CLOPROSTENOL; CONJUNCTIVAL DISEASES; CROSS-OVER STUDIES; FEMALE; GLAUCOMA; HEADACHE; HUMANS; HYPEREMIA; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; RETREATMENT; TREATMENT OUTCOME;

EID: 73349116866     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e318199722b     Document Type: Article

References (28)

1. American Academy of Ophthalmology. Primary Open-Angle Glaucoma, Preferred Practice Pattern. San Francisco: American Academy of Ophthalmology; 2005. Available at: www.aao.org. Accessed on: February 25, 2008.
2. Carroll SC, Gaskin BJ, Goldberg I, et al. Glaucoma prescribing trends in Australia and New Zealand. Clin Exp Ophthalmol. 2006;34:213-218.
3. Liu L. Australia and New Zealand survey of glaucoma practice patterns. Clin Exp Ophthalmol. 2008;36:19-25.
4. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713; discussion 729-730.
5. Konstas AG, Maskaleris G, Gratsonidis S, et al. Compliance and viewpoint of glaucoma patients in Greece. Eye. 2000; 14(Pt 5):752-756.
6. Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology. 2005;112:953-961.
7. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(suppl 4):S347-S351.
8. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-1304.
9. Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin- ethanolamides) and their pharmacology. Br J Pharmacol. 2007;154:1079-1093.
10. Dirks MS, Noecker RJ, Earl M, et al. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther. 2006;23:385-394.
11. Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112:262-266.
12. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressurelowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63.
13. DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001; 45(suppl 4):S353-S360.
14. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18: 110-121.
15. Parrish RK, Palmberg P, SheuWP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
16. Bournias TE, Lee D, Gross R, et al. Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 2003;19:193-203.
17. Law SK, Song BJ, Fang E, et al. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization. Ophthalmology. 2005;112:2123-2130.
18. Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther. 2002;19: 275-281.
19. Novack GD, David R, Lee PF, et al. Effect of changing medication regimens in glaucoma patients. Ophthalmologica. 1988;196:23-28.
20. Dinn RB, Zimmerman MB, Shuba LM, et al. Concordance of diurnal intraocular pressure between fellow eyes in primary open-angle glaucoma. Ophthalmology. 2007;114:915-920.
21. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 2003;110: 609-614.
22. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120: 1268-1279.
23. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56.
24. The Advanced Glaucoma Intervention Study Group. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429-440.
25. Weinreb R, Brandt J, Garway-Heath D, et al. Intraocular Pressure. The Hague: Kugler Publications; 2007:30-31.
26. Cohen JS, Gross RL, Cheetham JK, et al. Two-year doublemasked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49(suppl 1):S45-S52.
27. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002; 120:1286-1293.
28. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122:957-965.